Clinical Trial Results:
A PHASE II, MULTICENTER, RANDOMIZED, CONTROLLED, OPEN-LABEL STUDY OF THE SAFETY, EFFICACY AND PHARMACOKINETICS OF ABT-263 IN COMBINATION WITH DOSE-INTENSIVE RITUXIMAB, OR DOSE-INTENSIVE RITUXIMAB ALONE, IN PREVIOUSLY UNTREATED PATIENTS WITH B-CELL, CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Summary
|
|
EudraCT number |
2009-012152-24 |
Trial protocol |
CZ GB IT PL |
Global completion date |
15 Aug 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Jun 2016
|
First version publication date |
12 Jun 2016
|
Other versions |
|
Summary report(s) |
ABT-4710N Study |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.